Home » Stocks » Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. (CRNX)

Stock Price: $13.94 USD -0.66 (-4.52%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 458.40M
Revenue (ttm) 897,000
Net Income (ttm) -62.83M
Shares Out 32.88M
EPS (ttm) -2.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $13.94
Previous Close $14.60
Change ($) -0.66
Change (%) -4.52%
Day's Open 14.60
Day's Range 13.54 - 14.91
Day's Volume 171,131
52-Week Range 10.63 - 26.67

More Stats

Market Cap 458.40M
Enterprise Value 257.18M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.88M
Float 24.29M
EPS (basic) -2.44
EPS (diluted) -2.41
FCF / Share -1.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.42M
Short Ratio 15.97
Short % of Float 5.83%
Beta 1.16
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 511.03
PB Ratio 2.37
Revenue 897,000
Operating Income -65.15M
Net Income -62.83M
Free Cash Flow -55.24M
Net Cash 201.22M
Net Cash / Share 6.12
Gross Margin -4,494.20%
Operating Margin -7,263.55%
Profit Margin -7,004.50%
FCF Margin -6,158.19%
ROA -21.88%
ROE -36.44%
ROIC -91.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(143.90% upside)
Current: $13.94
Target: 34.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-50.86%18.73%247.2%-
Gross Profit1.192.432.050.59
Operating Income-53.83-28.71-9.13-6.04
Net Income-50.42-27.12-9.16-6.02
Shares Outstanding24.1812.141.371.01
Earnings Per Share-2.09-2.23-6.68-5.96
Operating Cash Flow-46.38-19.46-9.48-5.47
Capital Expenditures-0.49-1.06-0.30-0.19
Free Cash Flow-46.87-20.52-9.78-5.66
Cash & Equivalents11916414.1912.15
Total Debt4.85--0.21
Net Cash / Debt11416414.1911.94
Book Value117160-15.02-6.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Crinetics Pharmaceuticals, Inc.
Country United States
Employees 68
CEO Scott R. Struthers

Stock Information

Ticker Symbol CRNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRNX
IPO Date July 18, 2018


Crinetics Pharmaceuticals, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.